Literature DB >> 12522660

Bone marker alterations in patients with type 1 Gaucher disease.

G Ciana1, C Martini, A Leopaldi, G Tamaro, F Katouzian, L Ronfani, B Bembi.   

Abstract

Bone involvement is one of the most disabling aspects of type I Gaucher disease and its pathophysiology is still not well understood. As an invasive procedure, bone biopsies are not appropriate in a large population study. The development of sensitive bone resorption and formation tests have allowed the authors to study bone metabolism in a noninvasive manner in a group of type 1 Gaucher patients. Ten type I Gaucher adult patients with mild-to-severe bone disease were evaluated. Bone mineral density and markers of bone formation (total alkaline phosphatase and isoenzymes, carboxyterminal propeptide of type I procollagen, osteocalcin) and resorption (carboxyterminal telopeptide of type I collagen, urinary hydroxyproline, free-deoxypyridinoline and calcium) were measured in patients and in a control group, matched for sex and age. In Gaucher patients, carboxyterminal propeptide of type I procollagen (PICP), a bone formation index, was significantly lower compared with normal subjects (mean 101.17 ng/ml vs 140.75 ng/ml, P = 0.038), and analysis of bone resorption indexes showed a significant increase (mean 4.24 ng/ml vs 2.87 ng/ml, P = 0.012) of serum carboxyterminal telopeptide of type I collagen (ICTP). No significant differences were observed in osteocalcin, alkaline phosphatase, and urinary hydroxyproline. Bone mineral density revealed osteopenia in six patients, with a mean Z-score of ?1.04. It was not possible to show a relationship between sex, splenectomy status, age, weight, spleen, and liver volume and bone density, expressed as a Z-score nor a correlation between Z score and severity of skeletal disease. Results have shown a predominance of the resorption phase in the bone metabolism of Gaucher patients. These markers could be useful in monitoring the effect of enzyme replacement therapy on Gaucher disease skeletal involvement.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12522660     DOI: 10.1007/s00223-001-2072-0

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  7 in total

1.  Gaucher disease and bone: laboratory and skeletal mineral density variations during a long period of enzyme replacement therapy.

Authors:  G Ciana; R Addobbati; G Tamaro; A Leopaldi; M Nevyjel; L Ronfani; L Vidoni; M G Pittis; B Bembi
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

Review 2.  An overview on bone manifestations in Gaucher disease.

Authors:  Peter Mikosch; Derralynn Hughes
Journal:  Wien Med Wochenschr       Date:  2010-12

Review 3.  Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring.

Authors:  T M Cox; J M F G Aerts; N Belmatoug; M D Cappellini; S vom Dahl; J Goldblatt; G A Grabowski; C E M Hollak; P Hwu; M Maas; A M Martins; P K Mistry; G M Pastores; A Tylki-Szymanska; J Yee; N Weinreb
Journal:  J Inherit Metab Dis       Date:  2008-05-23       Impact factor: 4.982

4.  Gene variants of osteoprotegerin, estrogen-, calcitonin- and vitamin D-receptor genes and serum markers of bone metabolism in patients with Gaucher disease type 1.

Authors:  Anca Zimmermann; Radu A Popp; Heidi Rossmann; Simona Bucerzan; Ioana Nascu; Daniel Leucuta; Matthias M Weber; Paula Grigorescu-Sido
Journal:  Ther Clin Risk Manag       Date:  2018-10-24       Impact factor: 2.423

5.  Review of the safety and efficacy of imiglucerase treatment of Gaucher disease.

Authors:  Deborah Elstein; Ari Zimran
Journal:  Biologics       Date:  2009-09-15

6.  Bone turnover markers in patients with type 1 Gaucher disease.

Authors:  Gaetano Giuffrida; Maria Rocca Cingari; Nunziatina Parrinello; Alessandra Romano; Anna Triolo; Magda Franceschino; Francesco Di Raimondo
Journal:  Hematol Rep       Date:  2012-11-29

7.  A prospective study of bone marrow hematopoietic and mesenchymal stem cells in type 1 Gaucher disease patients.

Authors:  Séverine Lecourt; Enguerran Mouly; Delphine Freida; Audrey Cras; Raphaël Ceccaldi; Djazia Heraoui; Christine Chomienne; Jean-Pierre Marolleau; Bertrand Arnulf; Raphael Porcher; Catherine Caillaud; Valérie Vanneaux; Nadia Belmatoug; Jérôme Larghero
Journal:  PLoS One       Date:  2013-07-25       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.